Connect with pharmaceutical and healthcare regulatory authorities around the world via this directory.
Connect with pharmaceutical and healthcare regulatory authorities around the world via this directory.
View this resource in Pharmaceutical Technology’s September 2019 Regulatory Sourcebook.
FDA Approves Novartis Oral Treatment for Adults with C3 Glomerulopathy
March 25th 2025Fabhalta (iptacopan) received a positive opinion for treatment of C3G from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) and has been approved twice before by FDA.